Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 8/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8887892 | 0.91 | MAP4K4 (0.40) | MAP4K4PIK3CAEGFRKDRNPC1 | |
| SCHEMBL13660727 | 0.82 | MAP4K4 (0.36) | MAP4K4PIK3CAEGFRKDRDYRK1A | |
| SCHEMBL25776599 | 0.77 | MAP4K4 (0.44) | MAP4K4PIK3CADYRK1ADRD4DRD3 | |
| SCHEMBL30645085 | 0.77 | MAP4K4 (0.37) | MAP4K4PIK3CAEGFRKDRNPC1 | |
| SCHEMBL84746 | 0.76 | NPC1 (0.47) | MAP4K4DYRK1ANPC1RAB9ALMNA | |
| SCHEMBL10281634 | 0.74 | SRC (0.37) | CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL2991851 | 0.74 | NPC1 (0.42) | MAP4K4EGFRKDRDYRK1ANPC1 | |
| SCHEMBL24548207 | 0.73 | MAP4K4 (0.44) | MAP4K4PIK3CAEGFRKDRPTPN1 | |
| SCHEMBL9103578 | 0.73 | MAP4K4 (0.44) | MAP4K4PIK3CAEGFRKDRDYRK1A | |
| SCHEMBL9934420 | 0.73 | MAP4K4 (0.44) | MAP4K4PIK3CADYRK1ADRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023133181-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133183-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-11548890-B1 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| WO-2019200120-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | LYCERA CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| US-8785454-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140038970-A1 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575166-B2 | Phthalazine-containing antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120004234-A1 | PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110312967-A1 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2011-12-22 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7432373-B2 | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2008-10-07 | — | — | US | disclosed |
| EP-0244166-A2 | Heterocyclic acetyl sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004234-A1 | PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS | GPR119, FFAR2, FFAR1 | MAP4K4 2634/4885PIK3CA 1146/4885EGFR 2292/4885 |
| US-11548890-B1 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | MAP4K4 145/4885PIK3CA 821/4885EGFR 4399/4885 |
| US-20140038970-A1 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS | GPR119, FFAR2, FFAR1 | MAP4K4 2294/4885PIK3CA 1857/4885EGFR 1515/4885 |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | MAP4K4 147/4885PIK3CA 1099/4885EGFR 4666/4885 |
| US-20110312967-A1 | BRIDGED AND FUSED ANTIDIABETIC COMPOUNDS | GPR119, FFAR2, FFAR1 | MAP4K4 2384/4885PIK3CA 1864/4885EGFR 1553/4885 |
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | MAP4K4 149/4885PIK3CA 1181/4885EGFR 4733/4885 |
| US-20210087189-A1 | SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, SIK1 | MAP4K4 230/4885PIK3CA 860/4885EGFR 4752/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | MAP4K4 130/4885PIK3CA 1/4885EGFR 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.